Amol Akhade: CAR-T Data for CRC in ASCO 24
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on LinkedIn:
“CAR-T Data for CRC in ASCO 24.
GCC19 CART for metastatic CRC. Phase 1 study. Total 9 patients. For dose level 2, one out of 5 pts showed CMR on pet scan. One patient died due to sepsis post 48 days. 4 got partial responses. One SD.
This is interesting. But
We need to know how long the response lasted in that one pt with CMR and rest with PR. Generally such patient relapse in few months.
If it is long-lasting (beyond a year at least) then maybe it is worth trying in bigger clinical phase 3 trial.
Most of the times such response are short-lived and may be due to biology of disease per say rather than due to CAR-T use.”
More posts featuring Amol Akhade.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023